PIK75

• CAT Number: I003369
• CAS Number: 372196-77-5
• Molecular Formula: C₁₆H₁₅BrClN₅O₄S
• Molecular Weight: 488.74
• Purity: ≥95%
• Target: PI3K
• Solubility: DMSO ≥16mg/mL Water <1.2mg/mL Ethanol ≥4.6mg/mL
• Storage: 3 years -20C powder
• IC50: 5.8/2 nM(p110α/DNA-PK) [1] [2]
• InChI: InChI=1S/C16H14BrN5O4S.ClH/c1-11-3-5-13(22(23)24)7-15(11)27(25,26)20(2)19-9-14-8-18-16-6-4-12(17)10-21(14)16;/h3-10H,1-2H3;1H/b19-9+
• InChIKey: VOUDEIAYNKZQKM-MYHMWQFYSA-N
• SMILES: CC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)N(C)N=CC2=CN=C3N2C=C(C=C3)Br.Cl

PIK75 (Cat.No:I003369) is a selective inhibitor of phosphatidylinositol 3-kinase alpha (PI3Kα). It effectively targets the PI3K/AKT signaling pathway, which plays a crucial role in cell growth and survival. PIK75 has shown promise in preclinical studies for its potential anticancer activity, making it a valuable tool for cancer research and therapy development.

Reference

[1]. Zheng Z, et al. Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition. Mol Pharmacol. 2011, 80(4), 657-664.
[2]. WO/2003/072557, 09/04/2003
[3]. Moir LM, et al. Phosphatidylinositol 3-kinase isoform-specific effects in airway mesenchymal cell function. J Pharmacol Exp Ther. 2011, 337(2), 557-566.
[4]. Smirnova T, et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene. 2012, 31(6), 706-715.
[5]. Smith GC, et al. Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J. 2012, 442(1), 161-169.